Abstract
Background: A better understanding of predictors of risk for pancreatic ductal adenocarcinoma (PDAC) could inform preventive efforts against this lethal cancer. While aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDS) might protect against several gastrointestinal cancers, their role in the development of PDAC remains unclear. Aim: To conduct a systematic review and meta-analysis on the relation between ASA/NSAIDs exposure and the risk of PDAC. Methods: We searched Pubmed, Embase, Scopus, Cochrane database of systematic reviews and reference lists of identified papers and included observational (cohort or case-control) studies and randomized controlled trials examining exposure to ASA and/or NSAIDs and the incidence or mortality of PDAC. We defined three categories (low, intermediate, high), based on exposure duration and dose. Results: Eight studies fulfilled our inclusion criteria (four cohort, three case controls, and one randomized controlled trial studies) enrolling 6301 patients between 1971-2004; all but one study took place in the US. The pooled OR were 0.99 (0.83-1.19), 1.11 (0.84-1.47) and 1.09 (0.67-1.75) in the low, intermediate and high exposure groups respectively, with considerable heterogeneity (I2 ranging 60-86%). Sensitivity analysis by ASA use only, study design or sex did not reveal additional important information. Conclusions: This study did not show an association between ASA/NSAIDs and PDAC. The large baseline exposure in controls in North-America may have obscured an association. There is need for additional studies, especially in Europe, to clarify this issue.
| Original language | English |
|---|---|
| Pages (from-to) | 1089-1099 |
| Number of pages | 11 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 26 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Oct 2007 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Meta-analysis : The use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. / Capurso, G.; Schünemann, H. J.; Terrenato, I.; Moretti, A.; Koch, M.; Muti, P.; Capurso, L.; Delle Fave, G.
In: Alimentary Pharmacology and Therapeutics, Vol. 26, No. 8, 10.2007, p. 1089-1099.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Meta-analysis
T2 - The use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories
AU - Capurso, G.
AU - Schünemann, H. J.
AU - Terrenato, I.
AU - Moretti, A.
AU - Koch, M.
AU - Muti, P.
AU - Capurso, L.
AU - Delle Fave, G.
PY - 2007/10
Y1 - 2007/10
N2 - Background: A better understanding of predictors of risk for pancreatic ductal adenocarcinoma (PDAC) could inform preventive efforts against this lethal cancer. While aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDS) might protect against several gastrointestinal cancers, their role in the development of PDAC remains unclear. Aim: To conduct a systematic review and meta-analysis on the relation between ASA/NSAIDs exposure and the risk of PDAC. Methods: We searched Pubmed, Embase, Scopus, Cochrane database of systematic reviews and reference lists of identified papers and included observational (cohort or case-control) studies and randomized controlled trials examining exposure to ASA and/or NSAIDs and the incidence or mortality of PDAC. We defined three categories (low, intermediate, high), based on exposure duration and dose. Results: Eight studies fulfilled our inclusion criteria (four cohort, three case controls, and one randomized controlled trial studies) enrolling 6301 patients between 1971-2004; all but one study took place in the US. The pooled OR were 0.99 (0.83-1.19), 1.11 (0.84-1.47) and 1.09 (0.67-1.75) in the low, intermediate and high exposure groups respectively, with considerable heterogeneity (I2 ranging 60-86%). Sensitivity analysis by ASA use only, study design or sex did not reveal additional important information. Conclusions: This study did not show an association between ASA/NSAIDs and PDAC. The large baseline exposure in controls in North-America may have obscured an association. There is need for additional studies, especially in Europe, to clarify this issue.
AB - Background: A better understanding of predictors of risk for pancreatic ductal adenocarcinoma (PDAC) could inform preventive efforts against this lethal cancer. While aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDS) might protect against several gastrointestinal cancers, their role in the development of PDAC remains unclear. Aim: To conduct a systematic review and meta-analysis on the relation between ASA/NSAIDs exposure and the risk of PDAC. Methods: We searched Pubmed, Embase, Scopus, Cochrane database of systematic reviews and reference lists of identified papers and included observational (cohort or case-control) studies and randomized controlled trials examining exposure to ASA and/or NSAIDs and the incidence or mortality of PDAC. We defined three categories (low, intermediate, high), based on exposure duration and dose. Results: Eight studies fulfilled our inclusion criteria (four cohort, three case controls, and one randomized controlled trial studies) enrolling 6301 patients between 1971-2004; all but one study took place in the US. The pooled OR were 0.99 (0.83-1.19), 1.11 (0.84-1.47) and 1.09 (0.67-1.75) in the low, intermediate and high exposure groups respectively, with considerable heterogeneity (I2 ranging 60-86%). Sensitivity analysis by ASA use only, study design or sex did not reveal additional important information. Conclusions: This study did not show an association between ASA/NSAIDs and PDAC. The large baseline exposure in controls in North-America may have obscured an association. There is need for additional studies, especially in Europe, to clarify this issue.
UR - http://www.scopus.com/inward/record.url?scp=34748813750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748813750&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2007.03495.x
DO - 10.1111/j.1365-2036.2007.03495.x
M3 - Article
C2 - 17894651
AN - SCOPUS:34748813750
VL - 26
SP - 1089
EP - 1099
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 8
ER -